Még nem toboroz
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
NCT07781657· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Még nem toboroz
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT07116473· 3. fázis· Eidos Therapeutics, a BridgeBio company· Forrás
Toboroz
Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
NCT07158489· 2. fázis· Swiss Cancer Institute· Forrás
Toboroz
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
NCT07636811· 2. fázis· Alnylam Pharmaceuticals· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351· 1/2. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF
NCT07194382· 2. fázis· Avalyn Pharma Inc.· Forrás
Toboroz
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203· 3. fázis· Alnylam Pharmaceuticals· Forrás
Toboroz
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
NCT05974774· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895· 3. fázis· Eidos Therapeutics, a BridgeBio company· Forrás
Toboroz
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285· 3. fázis· Takeda· Forrás
Toboroz
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· 3. fázis· Revolution Medicines, Inc.· Forrás
Fut, nem toboroz
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06967805· 2. fázis· Mediar Therapeutics· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485· 3. fázis· Celgene· Forrás
Toboroz
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910· 3. fázis· Takeda· Forrás
Toboroz
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
NCT06276465· 3. fázis· UNICANCER· Forrás
Toboroz
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alterations.
2023-507684-19-00· 3. fázis· Janssen Cilag International· Forrás
Toboroz
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
2023-503699-25-00· 3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Toboroz
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
NCT06320067· 3. fázis· University College, London· Forrás
Fut, nem toboroz
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064· 1/2. fázis· Daiichi Sankyo· Forrás
Toboroz
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596· 2/3. fázis· Mirati Therapeutics Inc.· Forrás
Fut, nem toboroz
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
NCT04136353· 3. fázis· University of Sydney· Forrás
Fut, nem toboroz
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
NCT03924895· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
NCT02804815· 3. fázis· University College, London· Forrás
Fut, nem toboroz
Phase III Radium 223 mCRPC-PEACE III
NCT02194842· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Fut, nem toboroz
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
NCT02446405· 3. fázis· University of Sydney· Forrás